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Original Article
MicroRNA-96 Promotes Schistosomiasis
Hepatic Fibrosis in Mice by Suppressing Smad7
Xufeng Luo,1,4 Dongmei Zhang,1,4 Jun Xie,2,3 Qin Su,2 Xing He,1 Ruipu Bai,1 Guangping Gao,2,3 and Weiqing Pan1
1Department of Tropical Infectious Diseases, Second Military Medical University, Shanghai 200433, China; 2Horae Gene Therapy Center, University of Massachusetts
Medical School, Worcester, MA, USA; 3Department of Microbiology and Physiology Systems, University of Massachusetts Medical School, Worcester, MA, USA
Infection with Schistosoma causes aberrant expression of host
microRNAs (miRNAs), and normalizing the levels of dysregu-
lated miRNAs can attenuate pathology. Here, we show that
the host miRNA, miR-96, is markedly upregulated during the
progression of hepatic schistosomiasis. We demonstrate that
elevation of miR-96 induces hepatic ﬁbrosis in infected mice
by suppressing the expression of its target gene, Smad7. We
show that infection with Schistosoma induces the expression
of transforming growth factor b1 (TGF-b1), which in turn
upregulates the expression of miR-96 through SMAD2/3-
DROSHA-mediated post-transcriptional regulation. Further-
more, inhibition ofmiR-96with recombinant adeno-associated
virus 8 (rAAV8)-mediated delivery of Tough Decoy RNAs
in mice attenuated hepatic ﬁbrosis and prevented lethality
following schistosome infection. Taken together, our data high-
light the potential for rAAV8-mediated inhibition ofmiR-96 as
a therapeutic strategy to treat hepatic schistosomiasis.
INTRODUCTION
Schistosomiasis, also known as bilharzia, is a serious parasitic disease
that is common in tropical and subtropical regions. The schistosome
parasite infects approximately 210 million people worldwide, result-
ing in 120,000–200,000 deaths annually.1–3 Schistosoma japonicum
is endemic to Southeast Asia, where about 50 million people are at
risk for infection.4 The schistosome parasite undergoes a complex
life cycle involving multiple developmental stages. Following infec-
tion, the main pathology is granulomatous inﬂammation and hepatic
ﬁbrosis caused by the host response to schistosome eggs trapped in
the liver. Hepatic ﬁbrosis and the resulting portal hypertension are
the primary causes of host mortality.
The liver is composed of hepatocytes and resident non-parenchymal
cells such as hepatic stellate cells (HSCs) and Kupffer cells.5 The acti-
vation of HSCs is a key step in liver ﬁbrosis.6 Upon activation, HSCs
gradually transform into proliferative, contractile, and ﬁbrogenic my-
oﬁbroblasts. They secrete excess extracellular matrix (ECM) that is
deposited around damaged sites in the liver undergoing constant
wound repair, ultimately leading to ﬁbrosis.7,8 It has been shown
that schistosome infection activates HSCs distributed around the
periphery of egg-induced granulomas.4 Activated HSCs, in turn, pro-
duce IL13 and transforming growth factor b1 (TGF-b1), two major
mediators of schistosomiasis hepatic ﬁbrosis.9–11
MicroRNAs (miRNAs) play important roles in maintaining cellular
homeostasis under both normal and diseased conditions. Dysregula-
tion of miRNA expression is involved in ﬁbrosis of multiple organ
systems, including the vasculature (pulmonary ﬁbrosis), liver, and
kidney.12–14 Our previous study showed that increased expression
of miR-21 in HSCs in a murine model of schistosome infection acti-
vated Smad7, resulting in the induction of hepatic ﬁbrosis.15 More-
over, inhibition of miR-21 in infected mice with recombinant
adeno-associated virus-8 (rAAV8)-mediated delivery of Tough
Decoy RNAs (rAAV8-anti-miR-21-TuD) attenuated hepatic ﬁbrosis
by relieving the inhibitory effect of SMAD7 during SMAD
signaling.15 However, reduction ofmiR-21 only partially mitigates he-
patic ﬁbrosis, suggesting at the involvement of additional regulators.
Here, we report that host expression of miR-96 also plays a key role
in schistosomiasis hepatic ﬁbrosis by targeting smad7 in the TGF-
b1/SMAD pathway. Furthermore, recombinant AAV8-mediated
inhibition of miR-96 effectively attenuated this pathology, providing
protection against lethal infection of Schistosoma in the well-studied
murine model of the disease.
RESULTS
Identification of Hepatic Fibrosis-Relevant miRNAs and Their
Putative Targets
To identify host miRNAs that are involved in promoting schistoso-
miasis hepatic ﬁbrosis, we assessed the expression proﬁle of selected
miRNAs based on our previous data15 and those previously re-
ported to be involved in ﬁbrogenesis of S. japonicum-infected liver
tissues.14,16,17 We identiﬁed 29 upregulated (>2-fold) and 4 downre-
gulated (>2-fold) miRNAs from among 52 mouse miRNAs in in-
fected versus normal livers (Figure S1). Considering the key role
of HSCs in the progression of liver ﬁbrosis, we speciﬁcally assessed
the expression of these 29 miRNAs in the HSCs of normal and
S. japonicum-infected livers. As shown in Figure S2, miR-96 and
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three other miRNAs, miR-146, miR-184, and miR-2137, were highly
upregulated in HSCs of infected livers (>4-fold). We next searched
for putative targets of the highly upregulated miRNAs using miRNA
target prediction programs (http://www.microrna.org/microrna/
home.do). We found that SMAD7, a major inhibitory regulator of
TGF-b/SMAD signaling that is involved in ﬁbrogenesis, contained
multiple putative target sites for miR-96 (Figure S3). Using a
dual-luciferase reporter assay, we found that synthetic miR-96
mimics targeted the most conserved site in smad7, leading to 73%
reduction (relative luciferase activity [RLA] = 27.02 ± 6.14)
compared with the negative control (scrambled mimics, RLA =
100 ± 2.93). Conversely, when the target site was mutated, there
was no reduction of luciferase activity by miR-96mimics (Figure S4).
Thus, miR-96 was selected for further investigation into its potential
role in schistosomiasis hepatic ﬁbrosis.
Downregulation of miR-96 Prevents the Lethality of Mice
Following Schistosomiasis Infection
In an effort to treat schistosomiasis hepatic ﬁbrosis in vivo by
reducing levels of miR-96, we used the highly hepatotropic
rAAV8 vector to express TuDs for the sustained inhibition of
miR-96. The potency and speciﬁcity of the TuD-miR-96 constructs
were validated in HEK293 cells (Figure S5). Mice were infected with
a lethal dose of cercaria of S. japonicum and then injected intrave-
nously with the rAAV8-anti-miR-96-TuD vector, the control vector,
or PBS at 10 days post-infection (dpi) (Figure 1A). All mice
receiving a single dose of rAAV8-anti-miR-96-TuD vector (n = 5)
survived for the duration of the study (110 days), whereas in the
control groups (n = 5 each), three mice receiving the control vector
and four mice receiving PBS died within 90 dpi (Figure 1B). These
results indicate that a single dose of rAAV8-anti-miR-96-TuD
Figure 1. Downregulation of miR-96 Protects Mice
from Lethal Schistosome Infection
(A) Time schedule for schistosome infection and intrave-
nous injections of AAV8-anti-miRNA-TuD vectors or PBS.
Mice were infected percutaneously with 35 cercariae of
S. japonicum at day 0 and treated with various vectors at a
dose of 1  1012 viral genomes, or PBS by tail-vein in-
jection at 10 dpi. The animals were subjected to a 110-day
survival study. (B) Kaplan-Meier survival curves were
plotted for all groups as indicated.
signiﬁcantly protected infected mice from the
lethal effects of schistosomiasis.
Repression of miR-96 Mediated by rAAV8-
anti-miR-96-TuD Attenuates Hepatic
Fibrosis
To investigate the mechanism of rAAV8-anti-
miR-96-TuD-mediated protection against schis-
tosomiasis-induced lethality, we exposedmice to
a mild dose of S. japonicum cercaria and then
injected them with rAAV8-anti-miR-96-TuD
or controls as described above (Figure 2A). A mild dose was used to
achieve slower disease progression and prolonged survival to allow
for pertinent experimental observations to be carried out. We found
that miR-96 levels were signiﬁcantly reduced in the rAAV8-anti-
miR-96-TuD-treated group compared with those in the control
groups at 50 dpi (Figure 2B).We also measured several markers of he-
patic ﬁbrosis, including hydroxyproline content, collagen deposition,
and liver granulomas. Hydroxyproline content was reduced by
36.76% ± 2.24% and 34.61% ± 8.28% in the anti-miR-96-TuD-treated
group compared with those of the PBS and scramble control groups at
50 dpi (Figure 2C). Fibrosis as measured byMasson’s trichrome stain-
ing of collagen deposition in liver sections was also signiﬁcantly
reduced in the rAAV8-anti-miR-96-TuD-treated livers (5.05 ± 1.73)
compared with those of the PBS (8.55 ± 1.93) and scramble (8.50 ±
2.24) control groups (Figures 2D and 2E). Interestingly, liver granu-
lomas were also signiﬁcantly smaller in the rAAV8-anti-miR-96-
TuD group (110.76  103 ± 9.1  103 mm2) as compared with those
in the PBS (150.46  103 ± 11.73  103 mm2) and scramble
(140.14 103± 5.68 103mm2) control groups (Figure 2F). However,
when we examined the worm and egg burden recovered from infected
mice, we found no signiﬁcant differences among these groups, sug-
gesting that the rAAV-delivered TuD treatments had no effect on
the development and reproduction of the parasite. These data indi-
cated that the rAAV8-anti-miR-96-TuD-mediated inhibition of
miR-96 attenuates the pathological progression of hepatic ﬁbrosis in
the host, but has no effect on the life cycle of the parasite.
TGF-b1 PromotesmiR-96 Expression in HSCs through Post-
transcriptional Regulation
To investigate how schistosome infection causes upregulation of
miR-96 expression, we ﬁrst proﬁled expression levels of miR-96 in
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different cell types within the infected liver. As shown in Figure 3A,
elevated expression of miR-96 was observed in all cell types tested,
but primarily in hepatocytes (20-fold; p = 0.002) and HSCs
(15-fold; p = 0.003).
Previous studies have identiﬁed both TGF-b1 and IL13 as major
mediators of schistosomiasis hepatic ﬁbrosis by activating
HSCs.9–11 Our previous study demonstrated that both TGF-b1
and IL13 upregulated miR-21 expression in mouse primary HSCs
in vitro through SMAD signaling.15 We detected signiﬁcantly
elevated expression of these cytokines in primary HSCs isolated
from infected livers (Figure 3B). The simultaneous elevation of
miR-96 in infected livers prompted us to ask whether TGF-b1
and IL13 also mediate elevated miR-96 expression. We found
that exogenous expression of TGF-b1 in mouse primary HSCs
signiﬁcantly increased expression of miR-96 in a concentration-
and time-dependent manner, whereas the other cytokines had no
effect on miR-96 expression (Figures 3C–3E). It is worth
mentioning that IL13, a major mediator for miR-21 upregulation,14
resulted in only a slight and insigniﬁcant elevation of miR-96
expression.
We next investigated the regulation of miR-96 biogenesis. It is well-
known that miRNA expression is controlled at both transcriptional
and post-transcriptional levels.18,19 We ﬁrst proﬁled pri-miR-96 and
Figure 2. Downregulation of miR-96 Mediated by
rAAV8-Anti-miR-96-TuD Attenuated
Schistosomiasis-Induced Hepatic Fibrosis
(A) Time schedule for schistosome infection and intrave-
nous injections of viral vectors and sample withdraw. Mice
were percutaneously infected with 16 cercariae of
S. japonicum at day 0 or remained uninfected. The in-
fected mice received various vectors at a dose of 1012 viral
genomes or PBS at 10 dpi. Liver samples were collected
at 50 dpi. (B) qRT-PCR analysis of miR-96, miR-214,
miR-150, and miR-705 expression in liver samples at
50 dpi. (C) Collagen content of livers as determined by
hydroxyproline content. (D) Fibrosis scores measured
fromMasson’s trichrome staining of liver sections. (E) H&E
staining of liver sections (upper row). Masson’s trichrome
staining of collagen in liver sections (bottom line). Scale
bar, 100 mm. (F) Mean area of granuloma measured from
Mayer’s H&E staining of liver sections using a calibrated
measuring eyepiece. Data are represented as mean ± SD.
*p < 0.05; **p < 0.01, compared between indicated
groups.
pre-miR-96 expression in infected (50 dpi) versus
uninfected (0 dpi) mouse HSCs. We found that
the relative levels of both pri- and pre-miR-96
in infected HSCs were higher (2- and 4-
fold, respectively) than those in uninfected
HSCs (Figure 3F).We stimulatedmouse primary
HSCs in vitro with TGF-b1 and measured the
relative levels of pri- and pre-miR-96 at various time points post-stim-
ulation. Starting at 12 hr after stimulation, the levels of pre-miR-96
were signiﬁcantly increased over those of pri-miR-96 (Figure 3G).
These data suggest that elevation ofmiR-96 in infectedmice is achieved
mainly through post-transcriptional processing rather than transcrip-
tional regulation.
An earlier report indicated that miR-21 is upregulated through
post-transcriptional regulation involving a protein complex con-
sisting of DROSHA and activated SMAD 2/3 proteins.19 Our pre-
vious study showed that SMAD proteins were activated in HSCs
upon schistosome infection.15 To test whether the SMAD2/3-
DROSHA protein complex assembles on miR-96 in infected
HSCs, we performed an RNA-binding protein immunoprecipita-
tion (RIP) analysis.20 As shown in Figure 3H, both miR-21 and
miR-96 were signiﬁcantly enriched by anti-DROSHA and anti-
SMAD2/3 antibodies in HSCs of infected mice (50 dpi) and unin-
fected HSCs, but not by non-speciﬁc IgG. By contrast, miR-214 was
not detected regardless of the antibody used. These results indi-
cated that the elevation of miR-96 is mainly through post-tran-
scriptional regulation mediated by the SMAD2/3-DROSHA pro-
tein complex.
We further investigated whether TGF-b1 regulates miR-96 levels
through a post-transcriptional step that is mediated by the
www.moleculartherapy.org
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Figure 3. TGF-b1 Elevates miR-96 Expression through Post-transcriptional Regulation
(A) qRT-PCR analysis of miR-96 expression in isolated hepatocytes, HSCs, and Kupffer cells from mouse livers at 0 and 50 dpi, and the miR-96 expression in HSCs of the
wild-type mice at 0 and 50 dpi. (B) qRT-PCR analysis of tgf-b1 and il13 expression in the HSCs of infected mice. (C) qRT-PCR analysis of miR-96 and miR-214
expression in primary HSCs treated in vitro for 24 hr with IL10 (25 ng/mL), interferon (IFN)-g (25 ng/mL), TGF-b1 (100 ng/mL), and IL13 (200 ng/mL). (D) qRT-PCR
analysis of miR-96 expression in primary HSCs treated with different concentrations of TGF-b1 as indicated. (E) qRT-PCR analysis of miR-96 expression in primary HSCs
treated with TGF-b1 (8 ng/mL) for various times. (F) qRT-PCR analysis of pri-miR-96 and pre-miR-96 expression levels in isolated HSCs from mice at 0 and 50 dpi.
(G) qRT-PCR analysis of pri-miR-96 and pre-miR-96 expression in primary HSCs treated with TGF-b1 (10 ng/mL) for various times. (H) RNA-binding protein immu-
noprecipitation (RIP) analysis of post-transcriptional processing of miR-96. The cell lysates of HSCs isolated from infected (50 dpi) and uninfected (0 dpi) mice were
(legend continued on next page)
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SMAD2/3-DROSHA protein complex. Consistent with our
previous data, stimulation of mouse primary HSCs with either
TGF-b1 or Il13 resulted in the speciﬁc enrichment of miR-21 using
anti-DROSHA and anti-SMAD2/3 antibodies (Figure 3I). How-
ever, only stimulation with TGF-b1 led to signiﬁcant enrichment
of miR-96 (Figure 3I), suggesting that TGF-b1, rather than IL13,
is the primary mediator regulating cellular levels of miR-96. This
ﬁnding is consistent with the results described above (Figure 3C).
As expected, stimulation with both cytokines did not result in
enrichment of miR-214. Taken together, these results indicate
that TGF-b1 stimulates the elevation of miR-96 levels by
mainly activating Smad proteins and inducing the formation of a
complex composed of SMAD2/3, pri-miR-96, and subunits of the
microprocessor complex such as DROSHA.
miR-96 Induces Hepatic Fibrosis by Targeting smad7
SMAD7 is a major inhibitor of the ﬁbrogenesis-inducing TGF-b1/
SMAD signaling pathway. As described above, SMAD7 contains
Figure 4. Downregulation of miR-96 De-represses
Smad7, Reducing the Deposition of ECM in
Schistosome-Infected Livers
(A and B) RT-PCR analysis of miR-96 (A) and smad7 (B)
expression in HSCs isolated from uninfected and infected
mice administered with various rAAV8-TuD vectors as
indicated at 50 dpi. (C) Western blot analysis of SMAD7
expression in HSCs isolated from mice as described
above. (D and E) RT-PCR analysis of (D) col1 and (E) col3
expression in HSCs isolated from mice as described
above. Data are represented as mean ± SD. *p < 0.05;
**p < 0.01; ***p < 0.001, compared between indicated
groups.
multiple putative target sites for miR-96 (Fig-
ures S3 and S4). Transfection of the HSC-T6
cell line with a synthetic miR-96 inhibitor re-
sulted in a signiﬁcant 2-fold increase in
SMAD7 expression as detected by qRT-PCR
(Figure S6A) and Western blot analysis (Fig-
ure S6B), indicating that miR-96 is a regulator
of Smad7 expression. We used the miR-96 in-
hibitor to investigate the effect of elevated
smad7 expression on the production of col1
and col3, important biomarkers of ﬁbrosis.
In our previous study, we demonstrated that
upregulation of miR-21 drives elevated expres-
sion of col1 and col2.14 Here, we used an miR-
21 inhibitor as a positive control. We found
that transfection with the miR-96 inhibitor
signiﬁcantly upregulated smad7 expression in
the HSC-T6 cell line by 4-fold and signiﬁcantly reduced the
expression of col1 by 3-fold (Figure S6C). Levels of col3 were un-
changed. These results indicate that inhibition of miR-96 upregu-
lates smad7 expression and reduces expression of at least one
ﬁbrotic biomarker.
To further investigate whether downregulation of miR-96 in vivo can
reduce the expression of both col1 and col3 in HSCs, we infected mice
with parasites and then administered either rAAV8-anti-miR-96-
TuD or the scramble control vector, as described above (Figure 2A).
At 50 dpi, we isolated HSCs of infected mice and quantiﬁed the tran-
script levels of miR-96, smad7, col1, and col3. Similar to our results
above, rAAV8-anti-miR-96-TuD-mediated intervention signiﬁcantly
reduced miR-96 expression in isolated HSCs (Figure 4A). Impor-
tantly, the reduction in miR-96 led to signiﬁcantly increased Smad7
expression, as detected by qRT-PCR (Figure 4B, rAAV8-anti-miR-
96-TuD group) and by Western blot analysis (Figure 4C, lane 2).
These changes were also concomitant with decreases in col1 and
immunoprecipitated with anti-SMAD2+SMAD3, anti-DROSHA, or normal rabbit IgG and subjected to qRT-PCR analysis. (I) In vitro RIP analysis of post-transcriptional
processing of miR-96 and miR-21 maturation. qRT-PCR analysis of miR-96 and miR-21 expression in primary HSCs treated with TGF-b1 (100 ng/mL) or IL13
(200 ng/mL) for 24 hr. HSC lysates were immunoprecipitated and subjected to qRT-PCR analysis as described above. Data are represented as mean ± SD. *p < 0.05,
**p < 0.01, ***p < 0.001 compared between indicated groups.
www.moleculartherapy.org
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col3 expression (Figures 4D and 4E, rAAV8-anti-miR-96-TuD
group).
miR-96 and miR-21 Have an Additive Inhibitory Effect on
Expression of Smad7
We next searched the Smad7 gene for miR-96 and miR-21 bind-
ing sites. We identiﬁed two highly conserved binding motifs for
miR-21 and two highly conserved motifs for miR-96 in the 30
UTR of Smad7. Two additional poorly conserved motifs for
miR-96 were also identiﬁed elsewhere in the gene (Figure S3).
Thus, we hypothesized that the two miRNAs have additive effects
on regulating Smad7 expression. We ﬁrst transfected mouse pri-
mary HSCs with an miR-21 mimic, an miR-96 mimic, or both
mimics together. As expected, each miRNA mimic reduced
smad7 expression when tested individually (Figure 5A). Impor-
tantly, co-transfection with both mimics led to an additive reduc-
tion in expression of smad7 (Figure 5A). Consistent with this
observation, when we co-transfected HSC-T6 cells with inhibitors
of both miR-21 and miR-96, we observed an additive effect on the
upregulation of SMAD7 expression by Western blot analysis
(Figure 5B). Finally, we investigated the additive effect of both
miR-21 and miR-96 on Smad7 expression in vivo through
rAAV8-anti-96/21-TuD intervention. For this experiment, mice
were infected with a mild dose of S. japonicum cercaria and
then injected intravenously with either the rAAV8-anti-miR-96-
Figure 5.miR-96 andmiR-21Have an Additive Effect
on the Inhibition of Smad7 In Vitro
(A) RT-PCR analysis of smad7 expression in mouse pri-
mary HSCs transfected with mimics of miR-21, miR-96,
the combination of miR-21 and miR-96, or controls.
(B) Western blot analysis of SMAD7 in the HSC-T6 cell line
transfected with inhibitors of miR-21, miR-96, the com-
bination of miR-21 and miR-96, or controls. (C) Western
blot analysis of SMAD7 expression in liver samples from
uninfected and infected mice treated with the rAAV8-anti-
miR-96-TuD vector, the rAAV8-anti-miR-21-TuD vector,
the combination of both vectors, or control vectors.
(D) RT-PCR analysis of smad7 expression in mouse pri-
mary HSCs isolated from uninfected and infected mice
treated with the rAAV8-anti-miR-96-TuD vector, the
rAAV8-anti-miR-21-TuD vector, the combination of both
vectors, or the control vector. Data are represented as
mean ± SD. *p < 0.05; **p < 0.01, compared between
indicated groups.
TuD vector, the rAAV8-anti-miR-21-TuD
vector, or with both vectors. As shown in Fig-
ures 5C and 5D, the expression of Smad7 was
increased in infected mice treated with either
anti-miR-21-TuD or anti-miR-96-TuD vec-
tors, but not in those treated with the anti-
SCR-TuD vector or PBS. Importantly, the
additive effects on the elevated expression
of Smad7 were detected when infected mice
were treated with both rAAV8-anti-miR-96-TuD and rAAV8-
anti-miR-21-TuD vectors in combination.
DISCUSSION
There is increasing evidence that dysregulation of certain miR-
NAs is concomitant with tissue ﬁbrosis. For example, our previ-
ous study showed that miR-21 regulates schistosomiasis hepatic
ﬁbrosis through the SMAD pathway.15 Infection by the schisto-
some parasite signiﬁcantly upregulates miR-21 expression and
elicits ﬁbrogenesis by relieving the inhibitory effects of
SMAD7.15 In this study, we demonstrated that miR-96 also pro-
motes schistosomiasis hepatic ﬁbrosis by a similar mechanism.
Infection with schistosome induces TGF-b1 expression and
thereby upregulates miR-96 expression. Elevated miR-96 sup-
presses Smad7 expression by binding to three seed regions in
the 30 UTR of smad7. Interestingly, we also show an additive ef-
fect of miR-96 and miR-21 on expression of Smad7 in mice and
cell lines, and by transfecting mimics or inhibitors of miR-96
and miR-21. In addition, we also found that the upregulation
of miR-96 in activated HSCs takes place through post-transcrip-
tional regulation that is mediated by the SMAD2/3-DROSHA
protein complex. Elevated TGF-b1 that results from schistosome
infection leads to the phosphorylation and nuclear import of
SMAD2/3. Phospho-SMAD2/3 complexes with DROSHA and
promotes the maturation of miR-96. These ﬁndings provide
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new insights into the mechanism of schistosomiasis hepatic
ﬁbrosis through the alteration of host miRNAs.
miR-96 has been reported to be elevated in different malignancies
including hepatocellular carcinoma,21 colon cancer,22 urothelial can-
cer,23 esophageal cancer,24 breast cancer, and prostate cancer.25,26 It
plays an important role in tumor progression by targeting tumor
suppressors such as FOXO1 and AKT1S1,26–28 thus promoting cell
proliferation and invasion. miR-96 is also a sensory organ-related
miRNA. It is involved in the functional differentiation of hair cells,
and mutations in miR-96 cause progressive hearing loss.29 We now
report that miR-96 controls hepatic ﬁbrosis in the murine model of
human schistosomiasis by targeting the 30 UTR of smad7. Impor-
tantly, rAAV8-mediated inhibition of miR-96 in infected mice re-
sulted in elevated Smad7 expression and attenuation of hepatic
ﬁbrosis. Despite our previous report that other host miRNAs such
asmiR-21,miR-203, andmiR-351 play important roles in the progres-
sion of schistosomiasis hepatic ﬁbrosis, the novelty of this study is
unique from our previous work: (1) we demonstrated that schisto-
some infection upregulates the expression of miR-96 via SMAD2/3-
DROSHA-mediated post-transcriptional regulation in TGF-b1
signaling; (2) the elevated expression of miR-96 promotes liver
ﬁbrosis by targeting Smad7, an important inhibitor of TGF-b1
signaling; and (3) both miR-96 and miR-21 target the 30 UTR of
smad7 and have an additive effect on regulating Smad7 expression
in vitro and in vivo. It is clear that schistosome infection causes the
dysregulation of multiple host miRNAs, governing hepatic ﬁbrosis
through targeting various ﬁbrosis-related genes and their signal
pathways.
Previous studies have revealed the mechanism of the TGF-b1/SMAD
canonical pathway for modulating miRNA expression. Activated
SMAD proteins directly facilitate pri-miRNA transcription by bind-
ing SMAD binding element (SBE) motifs in the promoters of
miRNAs.30 The SMAD2/3-DROSHA protein complex also promotes
the maturation of miRNAs via post-transcriptional processing,
increasing levels of pre-miRNAs. Davis et al.19 reported that
TGF-b1 induces expression of miR-21 through promoting the pro-
cessing of pri-miR-21 into pre-miR-21. A recent study showed that
TGF-b1 upregulated miR-96 expression in adenocarcinoma cell lines
through direct interaction of the SMAD2/3/4 protein complex with
the promoter of pri-miR-96.26 In our current study, TGF-b1 had a
limited effect on miR-96 transcription. Instead, we demonstrate that
post-transcriptional processingmediated by the SMAD2/3-DROSHA
protein complex is a key regulator of miR-96 expression in the HSCs
of schistosomiasis-infected mice. Our result is consistent with the
TGF-b1-mediated post-transcriptional upregulation of miR-21 that
was previously reported.15,19
TGF-b1 is a key activator of HSCs in the progression of hepatic
ﬁbrosis.31 In the case of schistosomiasis infection, IL13 is an addi-
tional important mediator of HSC activation.32 We demonstrated
in our previous study that TGF-b1 and IL13 upregulate miR-21
expression through the SMAD pathway, and that both cytokines
have an additive effect on miR-21 upregulation. By contrast, in our
current study, we show that TGF-b1, but not IL13, signiﬁcantly ele-
vates the expression of miR-96 in mouse primary HSCs. In Figures
3C and 3I, we show that TGF-b1 is the main factor that upregulates
the expression ofmiR-96 instead of IL13. It is known that TGF-b1 in-
duces SMAD2/3 to form a complex with DROSHA, whereas IL13 in-
duces SMAD1/2 to form a complex with DROSHA. Therefore, we
propose that the SMAD2/3 complex, but not the SMAD1/2 complex,
could bind to the promoter of miR-96.
SMAD7 is a key inhibitory regulator of SMAD signaling. Decreased
expression of Smad7 is associated with tissue ﬁbrosis, whereas
elevated expression of Smad7 through gene transfer can block ﬁbro-
genesis.33,34 Our previous study indicated that elevated miR-21 upre-
gulates schistosomiasis ﬁbrogenesis in mice through binding the 30
UTR of smad7.15 In the current study, we show that infection with
schistosome parasite induces expression of TGF-b1, which elevates
miR-96 expression in HSCs mainly through post-transcriptional
regulation mediated by the SMAD2/3-Drosha protein complex.
Elevated miR-96 induces hepatic ﬁbrogenesis in the infected liver
by targeting the 30 UTR of smad7 via binding sites that are distinct
from those of miR-21. Importantly, the additive effects of miR-21
and miR-96 on relieving the inhibitory effect of Smad7 were detected
in both in vitro cell lines and an in vivo animal model. Thus, inhibi-
tion of both miR-96 and miR-21 should be an attractive strategy to
treat hepatic ﬁbrosis, including schistosomiasis hepatic ﬁbrosis. Re-
combinant AAV has shown great promise for in vivo gene transfer ap-
plications due mainly to its long-term episomal persistence, broad
tissue tropism, and low immunogenicity.35,36 We chose AAV8-based
vectors for our current study based on its strong liver tropism,
its safety, and efﬁcacy that has been displayed in multiple pre-
clinical and clinical studies.37,38 Importantly, we demonstrated that
a single administration of two vectors, rAAV8-anti-miR-96-TuD
and rAAV8-anti-miR-21-TuD, provided efﬁcient downregulation of
both miR-96 and miR-21 expression, leading to an additive increase
in Smad7 expression. Our data highlight the utility of using
rAAV8-mediated delivery of miRNA inhibitors as an adjuvant ther-
apy for ﬁbrosis.
MATERIALS AND METHODS
Mice and Parasite Infections
Six-week-old male BALB/c mice were purchased from the Experi-
mental Animal Center of Second Military Medicine University
(Shanghai, China). For infections, mice were injected percutaneously
with 16–30 cercariae of S. japonicum shed from lab-infected snails
(Oncomelania hupensis) obtained from the National Institute of Para-
sitic Disease, Chinese Center for Disease Control and Prevention. All
procedures performed on animals within this study were conducted
in accordance with and by approval of Second Military Medicine
University.
Cell Culture and Transfection
HSC-T6, HEK293, and mouse primary HSCs were maintained in
DMEM supplemented with 10% fetal bovine serum (FBS) plus
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50 mg/mL streptomycin and 50 IU penicillin, and transfected using
the Lipofectamine 2000 Transfection Reagent (Life Technologies).
Isolation of Primary Mouse HSCs, Hepatocytes, and Kupffer
Cells
Isolation of primary mouse HSCs, hepatocytes, and Kupffer cells was
conducted as described previously.39 In brief, after anesthetizing a
mouse, the hepatic portal vein was cannulated; then the line and
pump was connected for in situ perfusion. The inferior vena cava
was cut off gently and sequentially perfused with warmed 37C
EGTA buffer, pronase solution, and collagenase solution. The di-
gested liver was excised and minced thoroughly on a Petri dish,
then ﬁltered through a 100-mm nylon strainer to achieve a single-
cell solution. Cells were centrifuged and washed several times with
Gey’s balanced salt solution B (GBSS/B) buffer at 50  g, 5 min at
4C, to eliminate the majority of hepatocytes. After hepatocytes
were pelleted, the supernatant containing nonparenchymal cells
was further centrifuged at 580  g for 10 min at 4C. Nonparenchy-
mal cells were washed several times with GBSS/B solution until the
supernatant was clear. The supernatant was discarded, and nonparen-
chymal cells were resuspended with 2 mL GBSS/B buffer and loaded
on the top layer of an appropriate OptiPrep solution (11.2% OptiPrep
solution for HSC isolation and 19% OptiPrep solution for Kupffer
cells isolation), then centrifuged at 1,400 g for 20 min. After centri-
fugation, the HSCs or Kupffer cells are separated between two layers
of liquid. HSCs were further puriﬁed using negative selection with
magnetic CD11b antibody beads and magnetic columns (MACS;
Miltenyi, Auburn, CA). Kupffer cells were puriﬁed using positive
selection with magnetic CD11b antibody beads.
RNA Extraction and Analysis
Total RNA was extracted from cells using the TriPure isolation
system (Cat. no. 11667165001; Roche). The relative quantities of
miR-96 and other markers such as smad7, col1, and col3 were
measured from 500 ng of total RNA by qRT-PCR using the
LightCycler 480 SYBR Green I Master (Cat. 04887352001; Roche)
detection kit and the LightCycler 480II (Roche) instrument, and
determined by the comparative cycle threshold (CT) method using
snRNA U6 levels for normalization as recommended in the manu-
facturer’s instructions.
Immunoblot Assays
Immunoblot assays were performed on total cell lysates (50 mg) us-
ing anti-SMAD7 monoclonal and polyclonal antibodies (catalog
[Cat.] no. Ab124890; Abcam). The anti-GAPDH antibody (Cat.
no. Ab181602; Abcam) was used for normalization. IRDye 800CW
goat anti-rabbit IgG (Cat. no. 926-32211; LI-COR) was used as a
secondary antibody, and blots were visualized by the ODYSSEY Sa
(LI-COR) instrument.
Liver Histopathology and Fibrosis Measurements
Liver histopathology and ﬁbrosis measurements were conducted as
described previously.40 In brief, for measuring hydroxyproline, we
used the hydroxyproline assay kit (A030-3; Jiancheng Nanjing)
following procedures for 80- to 100-mg liver samples. The percent-
age of hydroxyproline was calculated using the following formula:
Hyp (mg/mg) = (ODsamples  ODblank/ODstandard  ODblank) 
5 mg/mL  (10 mL/sample weight), where OD is optical density.
To calculate granuloma sizes for each H&E slice, we measured the
area of 25 granulomas. Liver histopathology and ﬁbrosis were de-
tected by H&E staining and Masson’s staining. To evaluate the level
of ﬁbrosis, we calculated a ﬁbrosis score using the following for-
mula: ﬁbrosis score = degree of granuloma size  degree of blue
color; both degree values range from 1 to 4, and the ﬁbrosis scores
range from 1 to 16.
RIP Assay
Primary HSCs were isolated from uninfected and S. japonicum-in-
fected mouse livers and assayed with the EZ-Magna RIP RNA-Bind-
ing Protein Immunoprecipitation Kit (Cat. 17-701; Millipore). To
obtain concentrated cell lysates, at least 2  107 cells are required
for 100 mL of RIP Lysis Buffer. The assay was performed following
the manufacturer’s protocol with anti-SMAD2+SMAD3 (Cat. no.
ab65847; Abcam), anti-DROSHA antibodies (Cat. no. ab12286;
Abcam), and normal rabbit IgG as a negative control antibody
(Cat. no. PP64B; Millipore).
Dual-Luciferase Reporter Assay
The 30 UTR of smad7 was cloned into a modiﬁed pGL-3 control vec-
tor, with the 30 UTR placed downstream of the luciferase coding
sequence. The transfection mixtures contained 100 ng of ﬁreﬂy lucif-
erase reporter and 80 pM of miR-96 mimics. pRL-TK (Promega) was
transfected as an internal control. Fireﬂy luciferase activities were as-
sayed using the dual-luciferase assay (Cat. no. E1910; Promega) 48 hr
after transfection.
Construction of Plasmids and Vectors
The b-Gal gene was PCR-ampliﬁed from the pAAV2.1TBGLacZ
plasmid using primer claczF with a NheI site and claczR with a
XhoI site. The PCR fragment was cut with these two restriction en-
zymes and cloned into NheI and XhoI sites within the psiCHECK
plasmid. Three copies of perfectly complementary miR-96 sites
were designed based on the annotated miR-96 sequence and in-
serted between the XhoI and NotI restriction sites 30 of the b-Gal
gene to make the pmiCHECK-96 sensor plasmid. To express
miR-96, we ampliﬁed a pri-miR-96 fragment from mouse genomic
DNA using primers pri-miR-96F and pri-miR-96R and cloned
into the PpuMI site within the pAAVscCBPI-pGluc plasmid.
BamHI-digested anti-miR-96-TuD fragment (synthesized from
GenScript) was cloned into the BamHI site in pAAVscCBPI-TuD-
let-7p-Gluc following removal of anti-let-7-TuD. rAAV8 vectors
used in the study were produced, puriﬁed, and titered as described
previously.41
Statistical Analysis
Results are reported as mean ± SD and compared between groups us-
ing two-tailed Student’s t test, one-way ANOVA, or the Kaplan-Meier
Molecular Therapy: Methods & Clinical Development
80 Molecular Therapy: Methods & Clinical Development Vol. 11 December 2018
method. Data were considered statistically signiﬁcant for p values less
than 0.05.
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